Imidazenil: A Protective Agent Against Chemical Warfare Agents induced Status Epilepticus

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: DAMD17-05-C-0125
Agency Tracking Number: C051-116-0155
Amount: $70,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD05-116
Solicitation Number: 2005.1
Timeline
Solicitation Year: 2005
Award Year: 2005
Award Start Date (Proposal Award Date): 2005-05-17
Award End Date (Contract End Date): 2005-11-16
Small Business Information
513 Central Avenue, 5th Floor, Chicago, IL, 60063
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 James Auta
 Ph.D.
 (312) 355-4857
 jauta@psych.uic.edu
Business Contact
 Erminio Costa
Title: MD
Phone: (312) 413-4592
Email: ecosta@psych.uic.edu
Research Institution
N/A
Abstract
The overall objective of this proposal is to demonstrated that imidazenil is a more potent and safer protective agent than diazepam against chemical warfare nerve agent (CWNA)-induced seizure/status epilepticus, neuropathology, and neurobehavioral deficits. Thus we will compare the dose-dependent efficacy of imidazenil or diazepam administered alone and in combination with levetiracetam in protecting rats against diisopropyl fluorophosphate (DFP)-induced toxicity using the following 2 aims. Aim I: To evaluate the dose-dependent efficacies of imidazenil or diazepam administered alone or in combination with levetiracetam in the absence or presence of atropine and/or pralidoxime chloride (2-PAM) against DFP-induced seizure/status epilepticus and neurobehavioral deficits. This will be achieved by telemetric monitoring of cortical electroencephalogram (EEG), core temperature and motor activity. Aim II: To evaluate the effects of imidazenil or diazepam administered alone or in combination with levetiracetam in the absence or presence of atropine and/or 2-PAM on DFP-induced neuropathology. Rat brains will be examined for neuronal degeneration using the deoxyribonucleic acid (DNA) fragmentation measurement and light microscopy histological analysis. These studies may provide new information regarding the potential role of imidazenil in the treatment or prevention of CWNA poisoning and the potential role of the combination of levetiracetam and imidazenil in minimizing CWNA-induced neuropathology.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government